Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Knijnenburg, Sebastiaan L ^a   Mulder, Renée L ^b   Schouten Van Meeteren, Antoinette Y N ^b   Bökenkamp, Arend ^c   Blufpand, Hester ^c   van Dulmen den Broeder, Eline ^c   Veening, Margreet A ^c   Kremer, Leontien C M ^b   Jaspers, Monique W M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; MAGNESIUM; PHOSPHATE; ANTINEOPLASTIC AGENT;

BODY MASS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOVASCULAR RISK; CHILD; CHILDHOOD CANCER; CHRONIC KIDNEY FAILURE; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION TEST; MAGNESIUM BLOOD LEVEL; NEPHRECTOMY; NEPHROBLASTOMA; NEPHROTOXICITY; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADULT; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; MAGNESIUM DEFICIENCY; PHYSIOLOGY; RADIATION RESPONSE; RADIOTHERAPY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SURVIVOR; DRUG EFFECT; RADIATION EXPOSURE;

ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CISPLATIN; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPOPHOSPHATEMIA; IFOSFAMIDE; MAGNESIUM DEFICIENCY; NEPHRECTOMY; PROTEINURIA; RADIOTHERAPY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVORS;

EID: 84899612529     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008944.pub2     Document Type: Review

References (391)

1. Aronson DC, Slaar A, Heinen RC, de Kraker J, Heij HA. Long-term outcome of bilateral Wilms tumors (BWT). Pediatric Blood and Cancer 2011;56(7):1110-3.
2. Bardi E, Olah AV, Bartyik K, Endreffy E, Jenei C, Kappelmayer J, et al.Late effects on renal glomerular and tubular function in childhood cancer survivors. Pediatric Blood and Cancer 2004;43(6):668-73.
3. Bergeron C, Dubourg L, Chastagner P, Mechinaud F, Plouvier E, Desfachelles AS, et al.Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study. Pediatric Blood and Cancer 2005;45:32-6.
4. Bolling T, Ernst I, Pape H, Martini C, Rube C, Timmermann B, et al.Dose-volume analysis of radiation nephropathy in children: preliminary report of the RiSK Consortium. International Journal of Radiation Oncology, Biology and Physics 2010;80(3):840-4.
5. Breslow NE, Collins AJ, Ritchey ML, Grigoriev YA, Peterson SM, Green DM. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. Journal of Urology 2005;174:1972-5.
6. Brock PR, Koliouskas DE, Barratt TM, Yeomans E, Pritchard J. Partial reversibility of cisplatin nephrotoxicity in children. Journal of Pediatrics 1991;118:531-4.
7. Cardous-Ubbink MC, Geenen MM, Schade KJ, Heinen RC, Caron HN, Kremer LC, et al.Hypertension in long-term survivors of childhood cancer: a nested case-control study. European Journal of Cancer 2010;46:782-90.
8. Chevallier C, Hadj-Aissa A, Brunat-Mentigny M, Faraj G, Schell M, Cochat P. Renal function after nephrectomy for Wilms' tumor [Fonction rénale après néphrectomie pour tumeur de Wilms]. Archives de Pediatrie 1997;4:639-44.
9. Cosentino CM, Raffensperger JG, Luck SR, Reynolds M, Sherman JO, Reyes-Mugica M. A 25-year experience with renal tumors of childhood. Journal of Pediatric Surgery 1993;28:1350-4.
10. Cozzi F, Schiavetti A, Morini F, Zani A, Gambino M, Donfrancesco C, et al.Renal function adaptation in children with unilateral renal tumors treated with nephron sparing surgery or nephrectomy. Journal of Urology 2005;174:1404-8.
11. de Graaf SS, van Gent H, Reitsma-Bierens WC, van Luyk WH, Dolsma WV, Postma A. Renal function after unilateral nephrectomy for Wilms' tumour: the influence of radiation therapy. European Journal of Cancer 1996;32A:465-9.
12. Di Tullio MT, Casale F, Indolfi P, Polito C, Giuliano M, Martini A, et al.Compensatory hypertrophy and progressive renal damage in children nephrectomized for Wilms' tumor. Medical and Pediatric Oncology 1996;26(5):325-8.
13. English MW, Skinner R, Pearson AD, Price L, Wyllie R, Craft AW. Dose-related nephrotoxicity of carboplatin in children. British Journal of Cancer 1999;81(2):336-41.
14. Ferrari S, Pieretti F, Verri E, Tolentinis L, Cesari M, Versari M, et al.Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. Anticancer Drugs 2005;16(7):733-8.
15. Finklestein JZ, Norkool P, Green DM, Breslow N, D'Angio GJ. Diastolic hypertension in Wilms' tumor survivors: a late effect of treatment? A report from the National Wilms' Tumor Study Group. American Journal of Clinical Oncology 1993;16(3):201-5.
16. Frisk P, Bratteby LE, Carlson K, Lonnerholm G. Renal function after autologous bone marrow transplantation in children: a long-term prospective study. Bone Marrow Transplantation 2002;29(2):129-36.
17. Frisk P, Arvidson J, Stridsberg M, Gustafsson J. Normal long-term parathyroid function after autologous bone marrow transplantation in children. Pediatric Transplantation 2007;11(2):205-8.
18. Fujieda M, Matsunaga A, Hayashi A, Tauchi H, Chayama K, Sekine T. Children's toxicology from bench to bed-Drug-induced renal injury (2): nephrotoxicity induced by cisplatin and ifosfamide in children. Journal of Toxicological Science 2009;34(Suppl 2):251-7.
19. Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, van Leeuwen FE. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatric Blood and Cancer 2010;55(4):690-7.
20. Hamilton TE, Ritchey ML, Haase GM, Argani P, Peterson SM, Anderson JR, et al.The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. Annals of Surgery 2011;253(5):1004-10.
21. Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE. Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biology of Blood and Marrow Transplantion 2010;16(4):515-24.
22. Indolfi P, Di Tullio MT, Casale F, De Rosa E, Polito C. Letter to the editor: Kidney size and function after unilateral nephrectomy for wilms tumor: a longitudinal study. Medical and Pediatric Oncology 2001;37:485-6.
23. Kantor AF, Li FP, Janov AJ, Tarbell NJ, Sallan SE. Hypertension in long-term survivors of childhood renal cancers. Journal of Clinical Oncology 1989;7(7):912-5.
24. Kubiak R, Gundeti M, Duffy PG, Ransley PG, Wilcox DT. Renal function and outcome following salvage surgery for bilateral Wilms' tumor. Journal of Pediatric Surgery 2004;39(11):1667-72.
25. Laverdiere C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, et al.Long-term complications in survivors of advanced stage neuroblastoma. Pediatric Blood and Cancer 2005;45(3):324-32.
26. Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, et al.Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. Journal of Clinical Pharmacology 1999;39(5):454-61.
27. Makipernaa A, Koskimies O, Jaaskelainen J, Teppo AM, Siimes MA. Renal growth and function 11-28 years after treatment of Wilms' tumour. European Journal of Pediatrics 1991;150(6):444-7.
28. Mancini AF, Rosito P, Salmi S, Rondelli R, Alvisi P, Leopardi G, et al.Renal function in patients previously treated for Wilms tumor in infancy. Rivista Italiana di Pediatria 1996;22:882-8.
29. Mpofu C, Mann JR. Urinary protein/creatinine index in follow up of patients with Wilms' tumour after nephrectomy. Archives of Disease in Childhood 1992;67(12):1462-6.
30. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al.Long-term evaluation of Ifosfamide-related nephrotoxicity in children. Journal of Clinical Oncology 2009;27(32):5350-5.
31. Othman F, Guo CY, Webber C, Atkinson SA, Barr RD. Osteopenia in survivors of Wilms tumor. International Journal of Oncology 2002;20(4):827-33.
32. Patzer L, Ringelmann F, Kentouche K, Fuchs D, Zintl F, Brandis M, et al.Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplantion 2001;27(3):319-27.
33. Paulino AC, Wen BC, Brown CK, Tannous R, Mayr NA, Zhen WK, et al.Late effects in children treated with radiation therapy for Wilms' tumor. International Journal of Radiation Oncology, Biology and Physics 2000;46(5):1239-46.
34. Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC, et al.Progressive glomerular toxicity of ifosfamide in children. Medical and Pediatric Oncology 1996;27(3):149-55.
35. Rossi R, Ehrich JH. Partial and complete de Toni-Debre-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy. European Journal of Clinical Pharmacology 1993;44 Suppl 1:S43-5.
36. Rossi R, Danzebrink S, Hillebrand D, Linnenburger K, Ullrich K, Jurgens H. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Medical and Pediatric Oncology 1994;22(1):27-32.
37. Rossi R, Godde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, et al.Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. Journal of Clinical Oncology 1994;12(1):159-65.
38. Rossi RM, Kist C, Wurster U, Kulpmann WR, Ehrich JH. Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis. Pediatric Nephrology 1994;8(2):151-6.
39. Rossi R, Schafers P, Pleyer J, Postler C, Boos J, Jurgens H. The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment. International Journal of Pediatric Hematology/Oncology 1997;4:393-9.
40. Rossi R, Pleyer J, Schafers P, Kuhn N, Kleta R, Deufel T, et al.Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Medical and Pediatric Oncology 1999;32(3):177-82.
41. Sasso G, Greco N, Murino P, Sasso FS. Late toxicity in Wilms tumor patients treated with radiotherapy at 15 years of median follow-up. Journal of Pediatric Hematology and Oncology 2010;32(7):e264-7.
42. Schell M, Cochat P, Hadj-Aissa A, Bouffet E, Dubourg L, Brunat-Mentigny M. Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour. Pediatric Nephrology 1995;9:579-82.
43. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. European Journal of Cancer 2009;45(18):3213-9.
44. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatric Blood and Cancer 2010;54(7):983-9.
45. Srinivas M, Agarwala S, Padhy AK, Gupta AK, Bajpai M, Bhatnagar V, et al.Somatic growth and renal function after unilateral nephrectomy for Wilms' tumor. Pediatric Surgery International 1998;14(3):185-8.
46. Stefanowicz J, Owczuk R, Sierota D, Kaczorowska-Hac B, Balcerska A. Does antineoplasm treatment decrease the glomerular filtration rate in children?. Kidney and Blood Pressure Research 2009;32:194-9.
47. Stefanowicz J, Kosiak M, Kosiak W, Korbus-Kosiak A, Sierota D, Owczuk R. Cystatin C and parenchymal thickness/kidney length ratio in Wilms tumor survivors. Pediatric Blood and Cancer 2010;54:41-6.
48. Stefanowicz J, Kosiak M, Romanowicz G, Owczuk R, Adamkiewicz-Drozynska E, Balcerska A. Glomerular filtration rate and prevalence of chronic kidney disease in Wilms' tumour survivors. Pediatric Nephrology 2011;26(5):759-66.
49. Stohr W, Paulides M, Bielack S, Jurgens H, Treuner J, Rossi R, et al.Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatric Blood and Cancer 2007;48(4):447-52.
50. Stohr W, Paulides M, Bielack S, Jurgens H, Koscielniak E, Rossi R, et al.Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatric Blood and Cancer 2007;48(2):140-7.
51. Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, et al.Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplantation 2007;40(8):741-6.
52. Trobs RB, Hansel M, Friedrich T, Bennek J. A 23-year experience with malignant renal tumors in infancy and childhood. European Journal of Pediatric Surgery 2001;11(2):92-8.
53. Van Dijk IWEM, Oldenburger F, Cardous-Ubbink MC, Geenen MM, Heinen RC, de Kraker J, et al.Evaluation of late adverse events in long-term Wilms' tumor survivors. International Journal of Radiation Oncology Biology Physics 2010;78:370-8.
54. Van Why SK, Friedman AL, Wei LJ, Hong R. Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplantation 1991;7(5):383-8.
55. von Schweinitz D, Byrd DJ, Hecker H, Weinel P, Bode U, Burger D, et al.Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. European Journal of Cancer 1997;33(8):1243-9.
56. Weirich A, Ludwig R, Graf N, Abel U, Leuschner I, Vujanic GM, et al.Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Annals of Oncology 2004;15(5):808-20.
57. Wikstad I, Pettersson BA, Elinder G, Sokucu S, Aperia A. A comparative study of size and function of the remnant kidney in patients nephrectomized in childhood for Wilms' tumor and hydronephrosis. Acta Paediatrica Scandinavia 1986;75(3):408-14.
58. Abboud I, Porcher R, Robin M, de Latour RP, Glotz D, Socie G, et al.Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2009;15:1251-7.
59. Abd-El-Aal HH, Mokhtar MM, Habib EE, El-Kashef AT, Fahmy ES. Medulloblastoma: conventional radiation therapy in comparison to chemo radiation therapy in the post-operative treatment of high-risk patients. Journal of the Egyptian National.Cancer Institute 2005;17:301-7.
60. Abedi MR, Backman L, Bostrom L, Lindback B, Ringden O. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplantation 1990;6:121-6.
61. Aksnes LH, Bauer HC, Dahl AA, Fossa SD, Hjorth L, Jebsen N, et al.Health status at long-term follow-up in patients treated for extremity localized Ewing sarcoma or osteosarcoma: a Scandinavian Sarcoma Group study. Pediatric Blood and Cancer 2009;53:84-9.
62. Aleksa K, Woodland C, Koren G. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatric Nephrology 2001;16:1153-8.
63. Aleksa K, Ito S, Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. Journal of Laboratory and Clinical Medicine 2004;143:159-62.
64. Amato RJ, Ellerhorst J, Banks M, Logothetis CJ. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. European Journal of Cancer 1995;31A:2223-8.
65. Anderson T, Javadpour N, Schilsky R, Barlock A, Young RC. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treatment Reports 1979;63:1687-92.
66. Anderson P. Continuously improving ifosfamide/mesna: a winning combination. Pediatric Blood and Cancer 2010;55:599-600.
67. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology 1989;7:126-31.
68. Arai A, Sakamaki H, Tanikawa S, Akiyama H, Onozawa Y, Okamoto R, et al.[Hemolytic uremic syndrome after bone marrow transplantation]. Rinsho Ketsueki 1998;39:422-6.
69. Arakelyan N, Jais JP, Delwail V, Briere J, Moles-Moreau MP, Senecal D, et al.Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer 2010;116:4054-62.
70. Argueso LR, Ritchey ML, Boyle ET Jr, Milliner DS, Bergstralh EJ, Kramer SA. Prognosis of children with solitary kidney after unilateral nephrectomy. Journal of Urology 1992;148:747-51.
71. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Medical and Pediatric Oncology 1997;28:35-40.
72. Arjmandi-Rafsanjani K, Hooman N, Vosoug P. Renal function in late survivors of Iranian children with cancer: single centre experience. Indian Journal of Cancer 2008;45:154-7.
73. Arndt C, Tefft M, Gehan E, Anderson J, Jenson M, Link M, et al.A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. Journal of Pediatric Hematology and Oncology 1997;19:124-9.
74. Arndt C, Morgenstern B, Hawkins D, Wilson D, Liedtke R, Miser J. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Medical and Pediatric Oncology 1999;32:93-6.
75. Arriagada R, Averbeck D, Dahl AA, Darby S, Fossa S, Friberg S, et al.OECI Workshop on late side-effects of cancer treatments. European Journal of Cancer 2009;45:354-9.
76. Ashraf MS, Brady J, Breatnach F, Deasy PF, O'Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. European Journal of Pediatrics 1994;153:90-4.
77. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, et al.High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. Journal of Chemotherapy 2002;14:198-206.
78. Baker KS, Bresters D, Sande JE. The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children. Pediatric Clinics of North America 2010;57:323-42.
79. Barahmani N, Carpentieri S, Li XN, Wang T, Cao Y, Howe L, et al.Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro-Oncology 2009;11:292-300.
80. Bardi E, Bobok I, Olah AV, Olah E, Kappelmayer J, Kiss C. Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatric Nephrology 2004;19:1145-7.
81. Bardi E, Bobok I, Olah V, Kappelmayer J, Kiss C. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathology &OncologyResearch 2007;13:249-53.
82. Bashir H, Crom D, Metzger M, Mulcahey J, Jones D, Hudson MM. Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. Pediatric Blood and Cancer 2007;49:867-9.
83. Baudoin P, Provoost AP, Molenaar JC. Renal function up to 50 years after unilateral nephrectomy in childhood. American Journal of Kidney Disease 1993;21:603-11.
84. Berg EE. Osteogenic sarcoma. Orthopaedic Nursing 2006;25:348-9.
85. Beyzadeoglu M, Arpaci F, Surenkok S, Ozyigit G, Oysul K, Caglar K, et al.Acute renal toxicity of 2 conditoning regimens in patients undergoing autologous peripheral blood stem-cell transplantation: Total body irradiation-cyclophosphamide versus ifosfamide, carboplatin, etoposide. Saudi Medical Journal 2008;29:832-6.
86. Bhatia S. Late effects among survivors of leukemia during childhood and adolescence. Blood Cells, Molecules, and Diseases 2003;31:84-92.
87. Bhisitkul DM, Morgan ER, Vozar MA, Langman CB. Renal functional reserve in long-term survivors of unilateral Wilms tumor. Journal of Pediatrics 1991;118:698-702.
88. Boddy AV, English M, Pearson AD, Idle JR, Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. European Journal of Cancer 1996;32A:1179-84.
89. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al.Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. European Journal of Nuclear Medicine andMolecular Imaging 2008;35:1847-56.
90. Bonsib SM, Pei Y. The non-neoplastic kidney in tumor nephrectomy specimens: what can it show and what is important?. Advances in Anatomic Pathology 2010;17:235-50.
91. Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, et al.A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. Journal of Clinical Oncology 1988;6:1231-8.
92. Brade WP, Herdrich K, Kachel-Fischer U, Araujo CE. Dosing and side-effects of ifosfamide plus mesna. Journal of Cancer ResearchandClinical Oncology 1991;117 Suppl 4:S164-86.
93. Bradley J, Reft C, Goldman S, Rubin C, Nachman J, Larson R, et al.High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. International Journal of Radiation Oncology Biology Physics 1998;40:391-6.
94. Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. British Journal of Cancer 1992;Suppl 18:S36-40.
95. Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leukemia and Lymphoma 2002;43:2125-31.
96. Bürger D, Moorman-Voestermans CG, Mildenberger H, Lemerle J, Voute PA, Tournade MF, et al.The advantages of preoperative therapy in Wilms' tumour. A summarised report on clinical trials conducted by the International Society of Paediatric Oncology (SIOP). Zeitschrift für Kinderchirurgie 1985;40:170-5.
97. Burk CD, Restaino I, Kaplan BS, Meadows AT. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. Journal of Pediatrics 1990;117:331-5.
98. Cachat F, Guignard J-P. Chemotherapy in children and renal side-effects. Revue Medicale de la Suisse Romande 1996;116:985-93.
99. Cai J-Y, Tang J-Y, Pan C, Xu M, Xue H-L, Zhou M, et al.Results of RS-99 protocol for childhood solid tumors. World Journal of Pediatrics 2010;6:43-9.
100. Carlson K, Smedmyr B, Hagberg H, Oberg G, Simonsson B. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas. Bone Marrow Transplantation 1993;11:205-8.
101. Castleberry RP, Kun LE, Shuster JJ, Altshuler G, Smith IE, Nitschke R, et al.Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. Journal of Clinical Oncology 1991;9:789-95.
102. Chen XF, Zhou FJ, Han H, Qin ZK, Liu ZW, Yu SL, et al.[Transabdominal radical nephrectomy for renal cell carcinoma: an experience on 155 patients]. Ai.Zheng 2007;26:528-32.
103. Cheng JC, Schultheiss TE, Wong JY. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. International Journal ofRadiation Oncology, Biology, Physics 2008;71:1436-43.
104. Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 2007;110:2313-20.
105. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, et al.Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biology of Blood and Marrow Transplantation 2010;16(12):1674-81.
106. Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers ME, Martin PJ, et al.Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Annals of Internal Medicine 2011;155(1):21-32.
107. Cohen EP, Lawton CA, Moulder JE. Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron 1995;70:217-22.
108. Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JA, et al.Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. International Journal ofRadiation Oncology, Biology, Physics 2008;70:1546-51.
109. Cole CH, Pritchard S, Rogers PCJ, Davis JE, Phillips G, Ka Wah Chan. Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies. Medical and Pediatric Oncology 1994;23:464-9.
110. Conn JW, Cohen EL, McDonald WJ, Blough WM Jr, Lucas CP, Mayor GH, et al.The syndrome of hypertension, hyperreninemia and secondary aldosteronism associated with renal juxtaglomerular cell tumor (primary reninism). Transactions of theAssociationof AmericanPhysicians 1972;85:353-68.
111. Cosset JM, Socie G, Dubray B, Girinsky T, Fourquet A, Gluckman E. Single dose versus fractionated total body irradiation before bone marrow transplantation: radiobiological and clinical considerations. International Journal ofRadiation Oncology, Biology, Physics 1994;30:477-92.
112. Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplantation 2001;28:67-75.
113. Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H, et al.NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. Journal of Clinical Oncology 1997;15:3433-40.
114. Cozzi F, Schiavetti A, Ritchey ML, Green DM, Thomas PRM, Smith GR, et al.Nephron sparing surgery for unilateral Wilms' tumor [2]. Medical and Pediatric Oncology 1997;28:239-40.
115. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F. Nephron-sparing surgery for unilateral primary renal tumor in children. Journal of Pediatric Surgery 2001;36:362-5.
116. Cozzi F, Zani A, Schiavetti A, Morini F, DeGaetano V, Matrunola M, et al.Compensatory renal growth in children with unilateral renal tumor treated by nephron-sparing surgery or nephrectomy. European Journal of Pediatric Surgery 2007;17:382-6.
117. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al.Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. Journal of Clinical Oncology 2001;19:3091-102.
118. Crom WR, Evans WE, Pratt CB, Senzer N, Denison M, Green AA, et al.Cisplatin disposition in children and adolescents with cancer. Cancer Chemotherapy and Pharmacology 1981;6:95-9.
119. Culine S, Lhomme C, Kattan J, Duvillard P, Michel G, Droz J-P. Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary. European Journal of Cancer Part A: General Topics 1994;30:1239-44.
120. Curigliano G, Spitaleri G, Magni E, Lorizzo K, De Cobelli O, Locatelli M, et al.Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. Journal of Chemotherapy 2009;21:687-92.
121. D'Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, et al.The treatment of Wilms' tumor: results of the national Wilms' tumor study. Cancer 1976;38:633-46.
122. D'Aoust JC, Prestayko AW, Einhorn LH, Comis RL, Ginsberg SJ, Archambault WA, et al.Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: an analysis. Medical and Pediatric Oncology 1979;6:195-205.
123. De Gislain C, Dumas M, D'Athis P, Chapuis T, Mayer F, Fargeot P, et al.Plasma creatinine evolution in long term cisplatin therapy. Influence of drug addosications. Therapie 1990;45:423-7.
124. de Kraker J, Voute PA. Experience with ifosfamide in paediatric tumours. Cancer Chemotherapy and Pharmacology 1989;24 Suppl 1:S28-9.
125. Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, et al.Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer BiotherapyandRadiopharmaceuticals 2008;23:292-300.
126. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. Journal of Clinical Oncology 1991;9:1821-30.
127. Detaille T, Anslot C, de Clety SC. Acute kidney injury in paediatric bone marrow patients. Acta Clinica Belgica 2007;2 Suppl:401-4.
128. Dhaliwal RS, Adelman RD, Turner E, Russo JC, Ruebner B. Radiation nephritis with hypertension and hyperreninemia following chemotherapy: cure by nephrectomy. Journal of Pediatrics 1980;96:68-70.
129. Diavolitsis VM, Rademaker A, Boyle J, Kang Z, Kiel K, Mulcahy M, et al.Change in creatinine clearance over time following upper abdominal irradiation: a dose-volume histogram multivariate analysis. American Journal of Clinical Oncology 2010;34(1):53-7.
130. Dome JS, Huff V. Wilms tumor overview. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP editor(s). GeneReviews™. Seattle, USA: University of Washington, 1993.
131. Doz F, Pinkerton R. What is the place of carboplatin in paediatric oncology?. European Journal of Cancer Part A: General Topics 1994;30:194-201.
132. Druley TE, Hayashi R, Mansur DB, Zhang QJ, Barnes Y, Trinkaus K, et al.Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplantation 2009;43:307-14.
133. Dunkel IJ, Lee TC, Shi W, Beaverson KL, Novetsky D, Lyden D, et al.A phase II trial of carboplatin for intraocular retinoblastoma. Pediatric Blood and Cancer 2007;49:643-8.
134. Edgar AB, Morris EMM, Kelnar CJH, Wallace HB. Endocrinopathy after childhood cancer treatment. Long-term Follow-up of Survivors of Childhood Cancer. Basel: S Karger AG, 2009:159-80.
135. Eghbali H, Catry-Thomas I, Soubeyran P, Bonnel C, Hoerni B. Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients [Association d'etoposide, de cisplatine et d'ifosfamide (VPH) dans la chimiotherapie de "rattrapage" des lymphomes malins agressifs en progression ou en rechute. Etude sur 51 patients]. Bulletin du Cancer 1994;81:800-7.
136. Ehrlich RM, Goldman R, Kaufman JJ. Surgery of bilateral Wilms tumors: the role of renal transplantation. Journal of Urology 1974;111(3):277-81.
137. Eklof O, Ringertz H. Kidney size and growth in unilateral renal agenesis and in the remaining kidney following nephrectomy for Wilms' tumor. Acta Radiologica:Diagnosis(Stockholm) 1976;17(5A):601-8.
138. Emminger W, Emminger-Schmidmeier W, Peters C, Hawliczek R, Hocker P, Gadner H. Limited tolerance of intensified conditioning regimens in children receiving methotrexate/cyclosporin A for graft-versus-host disease prophylaxis. Pediatric Hematology and Oncology 1992;9:1-9.
139. England RJ, Haider N, Vujanic GM, Kelsey A, Stiller CA, Pritchard Jones K, et al.Mesoblastic nephroma: a report of the United Kingdom Children's Cancer and Leukaemia Group (CCLG). Pediatric Blood and Cancer 2011;56:744-8.
140. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR III, Fallon RJ, et al.Long-term outcomes in patients with stage IV neuroblastoma. Journal of Pediatric Surgery 2006;41:377-81.
141. Esiashvili N, Chiang K-Y, Hasselle MD, Bryant C, Riffenburgh RH, Paulino AC. Renal toxicity in children undergoing total body irradiation for bone marrow transplant. Radiotherapy and Oncology 2009;90:242-6.
142. Feig SA, Gamis AS, Hord JD, Kodish ED, Mueller BU, Werner EJ, et al.Long-term follow-up care for pediatric cancer survivors. Pediatrics 2009;123:906-15.
143. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al.Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. Journal of Clinical Oncology 2005;23:8845-52.
144. Feusner JH, Ritchey ML, Norkool PA, Takashima JR, Breslow NE, Green DM. Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: a report from the National Wilms Tumor Study Group. Pediatric Blood and Cancer 2008;50:242-5.
145. Feyer P, Hoffmann FA, Standke E, Kubel M, Helbig W. Acute and late effects in the course of and after total body irradiation with following bone marrow transplantation in patients with different forms of leukaemia. Folia Haematologica 1989;116:487-91.
146. Flentje M, Weirich A, Graf N, Potter R, Zimmerman H, Ludwig R. Abdominal irradiation in unilateral nephroblastoma and its impact on local control and survival. International Journal ofRadiation Oncology, Biology, Physics 1998;40:163-9.
147. Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, et al.Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009;115:3243-53.
148. Friedman K, Wallis T, Maloney KW, Hendrickson RJ, Mengshol S, Cadnapaphornchai MA. An unusual cause of pediatric hypertension. Journal of Pediatrics 2007;151:206-12.
149. Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, Guerrero-Avendano G, Zapata-Tarres M, Medina-Sanson A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatric Hematology and Oncology 2007;24:403-8.
150. Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007;109:549-55.
151. Garaventa A, Hartmann O, Bernard JL, Zucker JM, Pardo N, Castel V, et al.Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Medical and Pediatric Oncology 1994;22:11-4.
152. Gaynon PS. Carboplatin in pediatric malignancies. Seminars in Oncology 1994;21:65-76.
153. Geenen MM, Cardous-Ubbink MC, Kremer LCM, Van Den Bos C, Van Der Pal HJH, Heinen RC, et al.Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. Journal of the American Medical Association 2007;297:2705-15.
154. Gerke P, Filejski W, Robins HI, Wiedemann GJ, Steinhoff J. Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. Journal of Cancer ResearchandClinical Oncology 2000;126:173-7.
155. Gerstein J, Meyer A, Sykora KW, Fruhauf J, Karstens JH, Bremer M. Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT). Strahlentherapie und Onkologie 2009;185(11):751-5.
156. Gillis AM, Sutton E, Dewitt KD, Matthay KK, Weinberg V, Fisch BM, et al.Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. International Journal ofRadiation Oncology, Biology, Physics 2007;69:858-64.
157. Gobel U, Calaminus G, Teske C, Bamberg M, Bokkerink JP, Haas RJ, et al.BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89 [BEP/VIP bei Kindern und Jugendlichen mit malignen nichttestikularen Keimzelltumoren. Ein Vergleich der Behandlungsergebnisse der Therapiestudien MAKEI 83/86 und 89P/89]. Klinische Pädiatrie 1993;205:231-40.
158. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemotherapy and Pharmacology 1986;18:69-73.
159. Goren MP. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Medical and Pediatric Oncology 2003;41:186-9.
160. Goyal J, Sidana A, Georgiades CS, Rodriguez R. Renal function and oncologic outcomes after cryoablation or partial nephrectomy for tumors in solitary kidneys. Korean Journal of Urology 2011;52(6):384-9.
161. Graf N, Reinhard H. Wilms tumors. Diagnosis and therapy. Urologe A 2003;42:391-409.
162. Gratton MA, Smyth BJ. Cisplatin: continuous versus bolus. Journal of Pediatric Hematology/Oncology 2006;28:60-1.
163. Green DM, Donckerwolcke R, Evans AE, D'Angio GJ. Late effects of treatment for Wilms tumor. Hematology/Oncology Clinics of North America 1995;9:1317-27.
164. Green DM. Chemotherapy for the treatment of children and adolescents with malignant germ cell tumors. Journal of Clinical Oncology 2008;26:3297-8.
165. Gronroos MH, Jahnukainen T, Irjala K, Harkonen R, Hurme S, Mottonen M, et al.Comparison of glomerular function tests in children with cancer. Pediatric Nephrology 2008;23:797-803.
166. Gunes AM, Can E, Saglam H, Ilcol YO, Baytan B. Assessment of bone mineral density and risk factors in children completing treatment for acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 2010;32:e102-7.
167. Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clinical Pediatrics 2009;48:601-8.
168. Hadley GP, Mars M. Hypertension in a cohort of African children with renal tumours. Pediatric Surgery International 2006;22:219-23.
169. Hanly L, Chen N, Rieder M, Koren G. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert OpiniononDrug Safety 2009;8:155-68.
170. Hanna AM, Pham TH, Askegard-Giesmann JR, Grams JM, Iqbal CW, Stavlo P, et al.Outcome of adrenocortical tumors in children. Journal of Pediatric Surgery 2008;43:843-9.
171. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Investigational New Drugs 2000;18:281-9.
172. Hayashi K, Tsuchiya H, Yamamoto N, Shirai T, Yamauchi K, Takeuchi A, et al.Impact of serum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma. Journal of Orthopaedic Science 2009;14:253-8.
173. Hayes-Jordan A, Green H, Fitzgerald N, Xiao L, Anderson P. Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion. Journal of Pediatric Surgery 2010;45:1000-6.
174. Hazar V, Gungor O, Guven AG, Aydin F, Akbas H, Gungor F, et al.Renal function after hematopoietic stem cell transplantation in children. Pediatric Blood and Cancer 2009;53:197-202.
175. Hegde S, Coulthard MG. Renal agenesis and unilateral nephrectomy: what are the risks of living with a single kidney?. Pediatric Nephrology 2009;24:439-46.
176. Heikens J, Somers R, Behrendt H, Oldenburger F, Langeveld NE, Bakker PJ. Late sequelae of oncologic treatment in children [Late gevolgen van oncologische behandeling bij kinderen]. Nederlands Tijdschrift voor Geneeskunde 1998;142:2191-5.
177. Heikens J, Ubbink MC, van der Pal HP, Bakker PJ, Fliers E, Smilde TJ, et al.Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer 2000;88:2116-21.
178. Helenglass G, Powles RL, McElwain TJ, Lakhani A, Milan S, Gore M, et al.Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplantation 1988;3:21-9.
179. Henderson T, Patel S, Levine J, Oeffinger KC. Follow-up of childhood cancer survivors: the role of the primary care physician. Consultant 2008;48:438-42.
180. Hingorani S. Chronic kidney disease after pediatric hematopoietic cell transplant. Biology of Blood and Marrow Transplantation 2008;14:84-7.
181. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, et al.Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. Journal of Clinical Oncology 1991;9:62-9.
182. Hovi L, Koskimies O, Holmberg C, Rajantie J, Rautonen J, Siimes MA. Risk of progressive kidney damage after acute leukemia. Acta Paediatrica Scandinavia 1989;78:608-14.
183. Hudson MM. Survivors of childhood cancer: coming of age. Hematology/Oncology Clinics of North America 2008;22:211-31.
184. Iida S, Kondo T, Amano H, Nakazawa H, Ito F, Hashimoto Y, et al.Minimal effect of cold ischemia time on progression to late-stage chronic kidney disease observed long term after partial nephrectomy. Urology 2008;72:1083-8.
185. Ippolito G, Palazzo FF, Sebag F, Sierra M, De Micco C, Henry JF. A single-institution 25-year review of true parathyroid cysts. Langenbeck's Archives of Surgery 2006;391:13-8.
186. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. The Lancet Oncology 2010;11:670-8.
187. Jereb B. Radiotherapy in nephroblastoma. Pre- and postoperative combination treatment. Radiotherapy in localized (stage II, III, IV) and metastatic disease. Actue and long-term side effects. Radiology and Oncology 1997;31:48-53.
188. Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin. CurrentOpinionin Pediatrics 1995;7:208-13.
189. Jones DP, Spunt SL, Green D, Springate JE. Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatric Blood and Cancer 2008;51:724-31.
190. Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, et al.Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia 1996;10:396-401.
191. Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, et al.Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009;115:5828-35.
192. Keaney CM, Springate JE. Cancer and the kidney. Adolescent MedicineClinics 2005;16:121-48.
193. Kenney LB, Nancarrow CM, Najita J, Vrooman LM, Rothwell M, Recklitis C, et al.Health status of the oldest adult survivors of cancer during childhood. Cancer 2010;116:497-505.
194. Kibirige MS, Morris-Jones PH, Addison GM. Prevention of cisplatin-induced hypomagnesemia. Pediatric Hematology and Oncology 1988;5:1-6.
195. Kim TH, Freeman CR, Webster JH. The significance of unilateral radiation nephropathy. International Journal ofRadiation Oncology, Biology, Physics 1980;6:1567-71.
196. Kim A, Gillespie A, Dombi E, Goodwin A, Goodspeed W, Fox E, et al.Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology 2009;73:1273-9.
197. Kirch C, Gachot B, Germann N, Blot F, Nitenberg G. Recurrent ifosfamide-induced hyponatraemia. European Journal of Cancer 1997;33:2438-9.
198. Kist-van Holthe JE, Goedvolk CA, Brand R, van Weel MH, Bredius RG, van Oostayen JA, et al.Prospective study of renal insufficiency after bone marrow transplantation. Pediatric Nephrology 2002;17:1032-7.
199. Kist-van Holthe JE, Ho PL, Stablein D, Harmon WE, Baum MA. Outcome of renal transplantation for Wilms' tumor and Denys-Drash syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatric Transplantation 2005;9:305-10.
200. Koren G, Schechter T. Cancer chemotherapy in young children: challenges and solutions. Pediatric Blood and Cancer 2007;49:1091-2.
201. Kourti M, Tragiannidis A, Makedou A, Papageorgiou T, Rousso I, Athanassiadou F. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. Journal of Pediatric Hematology/Oncology 2005;27:499-501.
202. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, et al.High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplantation 2002;30:893-8.
203. Kremers A, Langer T, Stohr W, Beck JD, Rascher W. Late effects of oncological therapy in children. Padiatrische Praxis 2003;64:47-64.
204. Kumar M, Kedar A, Neiberger RE. Kidney function in long-term pediatric survivors of acute lymphoblastic leukemia following allogeneic bone marrow transplantation. Pediatric Hematology and Oncology 1996;13:375-9.
205. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, et al.Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. Journal of Pediatric Hematology/Oncology 1995;17:265-9.
206. Kurt BA, Armstrong GT, Cash DK, Krasin MJ, Morris EB, Spunt SL, et al.Primary care management of the childhood cancer survivor. Journal of Pediatrics 2008;152:458-66.
207. Kusumi E, Kami M, Hara S, Hoshino J, Yamaguchi Y, Murashige N, et al.Postmortem examination of the kidney in allogeneic hematopoietic stem cell transplantation recipients: possible involvement of graft-versus-host disease. International Journal of Hematology 2008;87:225-30.
208. Landier W, Bhatia S. Cancer survivorship: a pediatric perspective. Oncologist 2008;13:1181-92.
209. Langer T, Stohr W, Bielack S, Paulussen M, Treuner J, Beck JD. Late effects surveillance system for sarcoma patients. Pediatric Blood and Cancer 2004;42:373-9.
210. Leahey AM, Teunissen H, Friedman DL, Moshang T, Lange BJ, Meadows AT. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Medical and Pediatric Oncology 1999;32:163-9.
211. Le Bourgeois JP, Meignan M, Parmentier C, Tubiana M. Renal consequences of irradiation of the spleen in lymphoma patients. British Journal of Radiology 1979;52:56-60.
212. Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, et al.Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatric Nephrology 2001;16:796-9.
213. Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G, et al.The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. Journal of Clinical Oncology 1993;11:1300-5.
214. Liesner RJ, Leiper AD, Hann IM, Chessells JM. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. Journal of Clinical Oncology 1994;12:916-24.
215. Lonnerholm G, Carlson K, Bratteby LE, Backlund L, Hagberg H, Rikner G, et al.Renal function after autologous bone marrow transplantation. Bone Marrow Transplantation 1991;8:129-34.
216. Ludwig R, Weirich A, Potter R, Harms D, Burger D, Michaelis J, et al.Preoperative chemotherapy of nephroblastoma. Preliminary results of the SIOP-9/GPO therapy study [Praoperative Chemotherapie des Nephroblastoms. Vorlaufige Ergebnisse der Therapiestudie SIOP-9/GPO.]. Klinische Pediatrie 1992;204:204-13.
217. Macklis RM, Oltikar A, Sallan SE. Wilms' tumor patients with pulmonary metastases. International Journal ofRadiation Oncology, Biology, Physics 1991;21:1187-93.
218. Macleod PM, Tyrell CJ, Keeling DH. The effect of cisplatin on renal function in patients with testicular tumours. Clinical Radiology 1988;39:190-2.
219. Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2009;15:1100-7.
220. Makari JH, Ramachandra P, Ferrer FA. Pediatric urologic oncology: organ-sparing surgery in kidney and testis. Urologic Clinics of North America 2010;37:287-98.
221. Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, et al.There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. International Journal ofRadiation Oncology, Biology, Physics 1999;43:959-64.
222. Marina NM, Wilimas JA, Meyer WH, Jones DP, Douglass EC, Pratt CB. Refining therapeutic strategies for patients with resistant Wilm's tumor. American Journal of Pediatric Hematology/Oncology 1994;16:296-300.
223. Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. Journal of Pediatric Hematology/Oncology 2000;22:112-8.
224. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-41.
225. Mashhadi MA, Sanadgol H, Keikhaei M. Ifosfamide nephropathy in patients with sarcoma. Iranian Journal of Kidney Disease 2011;5(4):238-41.
226. Massimi L, Tufo T, Di Rocco C. Management of optic-hypothalamic gliomas in children: still a challenging problem. Expert ReviewofAnticancer Therapy 2007;7:1591-610.
227. McCune JS, Friedman DL, Schuetze S, Blough D, Magbulos M, Hawkins DS. Influence of Age Upon Ifosfamide-Induced Nephrotoxicity. Pediatric Blood and Cancer 2004;42:427-32.
228. McCune JS, Batchelder A, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B, et al.Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clinical Pharmacology & Therapeutics 2009;85:615-622.
229. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al.Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Annals of Internal Medicine 1993;118:255-67.
230. Meacham LR, Chow EJ, Ness KK, Kamdar KY, Chen Y, Yasui Y, et al.Cardiovascular risk factors in adult survivors of pediatric cancer-a report from the childhood cancer survivor study. Cancer Epidemiology, Biomarkers and Prevention 2010;19:170-81.
231. Meadows AT, Silber J. Delayed consequences of therapy for childhood cancer. CA-A Cancer Journal for Clinicians 1985;35:271-86.
232. Meck MM, Leary M, Sills RH. Late effects in survivors of childhood cancer. Pediatrics in Review 2006;27:257-63.
233. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al.Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncologica 2006;45:831-7.
234. Mertens R, Granzen B, Lassay L, Gademann G, Hess CF, Heimann G. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Cancer 1997;80:951-9.
235. Meyer JP, Delves GH, Sullivan ME, Keoghane SR. The effect of nephroureterectomy on glomerular filtration rate. British Journal of UrologyInternational 2006;98:845-8.
236. Millar AJ, Davidson A, Rode H, Numanoglu A, Hartley PS, Desai F. Nephron-sparing surgery for bilateral Wilms' tumours: a single-centre experience with 23 cases. African Journal of Paediatric Surgery 2011;8(1):49-56.
237. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, et al.Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. Journal of Clinical Oncology 1996;14:579-85.
238. Miralbell R, Sancho G, Bieri S, Carrio I, Helg C, Brunet S, et al.Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. International Journal ofRadiation Oncology, Biology, Physics 2004;58:809-16.
239. Mitchell C, Hall G, Clarke RT. Acute leukaemia in children: diagnosis and management. British Medical Journal 2009;338:1491-5.
240. Moghrabi A, Friedman HS, Ashley DM, Bottom KS, Kerby T, Stewart E, et al.Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas. Neurosurgical Focus 1998;4:e3.
241. Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N. Cisplatin-induced hypokalemic paralysis. Clinical Therapeutics 2004;26:1320-3.
242. Morris Jones PH. The late effects of cancer therapy in childhood. British Journal of Cancer 1991;64:1-2.
243. Naguib SF, El Haddad A, El Badawy SA, Zaghloul AS. Multidisciplinary approach to wilms' tumor: a retrospective analytical study of 53 patients. Journal of theEgyptian National Cancer Institute 2008;20:410-23.
244. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. British Journal of Clinical Pharmacology 2007;64:151-64.
245. Niethammer D, Mayer E. Long-term survivors: an overview on late effects, sequelae and second neoplasias. Bone Marrow Transplantation 1998;21:S61-3.
246. Nieto B, Martin Aguado MJ, Verdu J, Canals A, Martin Hortiguela ME, Mira J, et al.Study of renal function and compensatory changes in children with single kidney [Determinacion de funcion renal y cambios compensadores en ninos con rinon unico]. Cirugía Pediátrica 2005;18:151-5.
247. Nogueira PCK, Hadj-Aissa A, Schell M, Dubourg L, Brunat-Mentigny M, Cochat P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatric Nephrology 1998;12:572-5.
248. Nunez SB, Mulrooney DA, Laverdiere C, Hudson MM. Risk-based health monitoring of childhood cancer survivors: a report from the Children's Oncology Group. Current Oncology Reports 2007;9:440-52.
249. Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews TC, Germak JA, et al.Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 2001;23:424-30.
250. Oeffinger KC, Adams-Huet B, Victor RG, Church TS, Snell PG, Dunn AL, et al.Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2009;27:3698-704.
251. Ota K. [Cisplatinum compounds]. Gan To Kagaku Ryoho 1993;20:50-8.
252. Pahernik S, Roos F, Wiesner C, Thuroff JW. Nephron sparing surgery for renal cell carcinoma in a solitary kidney. World Journal of Urology 2007;25:513-7.
253. Parigi GB, Beluffi G, Corbella F, Matteotti C, Ramella B, Bragheri R. Long-term follow-up in children treated for retroperitoneal malignant tumours. European Journal of Pediatric Surgery 2003;13:240-4.
254. Parisi MT, Fahmy JL, Kaminsky CK, Malogolowkin MH. Complications of cancer therapy in children: a radiologist's guide. Radiographics 1999;19:283-97.
255. Patte C, Philip T, Rodary C, Zucker JM, Behrendt H, Gentet JC, et al.High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. Journal of Clinical Oncology 1991;9:123-32.
256. Patzer L, Hempel L, Ringelmann F, Misselwitz J, Fuchs D, Zintl F, et al.Renal function after conditioning therapy for bone marrow transplantation in childhood. Medical and Pediatric Oncology 1997;28:274-83.
257. Paulides M, Mergenthaler A, Peeters J, Beck JD, Langer T, Kaatsch P. Major organ-related long-term effects of chemotherapy and secondary malignancies. Medizinische Welt 2008;59:105-9.
258. Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Kamposioras K, Tountas N, et al.Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors. UrologicOncology 2010;28(6):617-23.
259. Pentheroudakis G, Pavlidis N. Late toxicity in survivors from adolescent cancers. Cancer Treatment Reviews 2007;33:656-63.
260. Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, van Thiel SW, et al.High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clinical Endocrinology 2005;62:197-204.
261. Petersen FB, Deeg HJ, Buckner CD, Appelbaum FR, Storb R, Clift RA, et al.Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide-a phase I trial. International Journal ofRadiation Oncology, Biology, Physics 1992;23:1027-32.
262. Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Annals of Oncology 1999;10:1475-83.
263. Phillips RS, Tyerman K, Al-Kassim MI, Picton S. A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers. Pediatric Hematology and Oncology 2008;25:107-13.
264. Pietila S, Ala-Houhala M, Lenko HL, Harmoinen AP, Turjanmaa V, Makipernaa A. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment. Pediatric Blood and Cancer 2005;44:363-9.
265. Pietila S, Makipernaa A, Sievanen H, Koivisto AM, Wigren T, Lenko HL. Obesity and metabolic changes are common in young childhood brain tumor survivors. Pediatric Blood and Cancer 2009;52:853-9.
266. Pinter AB, Hock A, Kajtar P, Dober I. Long-term follow-up of cancer in neonates and infants: a national survey of 142 patients. Pediatric Surgery International 2003;19:233-9.
267. Plowman PN. Survivors of cancer: organ preservation and reducing the morbidity of treatment in paediatric genitourinary oncology. British Journal of Urology International 1999;83 Supp:51-60.
268. Pochedly C. Hyperuricemia in leukemia and lymphoma. I. Clinical findings and pathophysiology. New York State Journal of Medicine 1973;73:1085-92.
269. Ponisch W, Niederwieser D. Late effects after chemotherapy. Internist 2006;47:266-73.
270. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al.A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. ClinicalGastroenterology andHepatology 2007;5:1100-8.
271. Pratt CB, Hayes A, Green AA, Evans WE, Senzer N, Howarth CB, et al.Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treatment Reports 1981;65:1021-6.
272. Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ, et al.Ifosfamide, Fanconi's syndrome, and rickets. Journal of Clinical Oncology 1991;9:1495-9.
273. Pratt CB. Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. Seminars in Oncology 1996;23:84-90.
274. Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, et al.Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. American Journal of Pediatric Hematology/Oncology 1994;16:286-95.
275. Regazzoni BM, Genton N, Pelet J, Drukker A, Guignard JP. Long-term followup of renal functional reserve capacity after unilateral nephrectomy in childhood. Journal of Urology 1998;160:844-8.
276. Reisi N, Azhir A, Hashemipour M, Raeissi P, Amini A, Moafi A. The metabolic syndrome in survivors of childhood acute lymphoblastic leukemia in Isfahan, Iran. Journal of Research in Medical Sciences 2009;14:111-6.
277. No authors listed. Renal tumours and hypertension. British Medical Journal 1968;3(5614):327-8.
278. Ritchey ML, Green DM, Thomas PR, Smith GR, Haase G, Shochat S, et al.Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Medical and Pediatric Oncology 1996;26:75-80.
279. Ritchey M. Renal sparing surgery for children with bilateral Wilms tumor. Cancer 2008;112:1877-8.
280. Roback SA, Nesbit ME Jr, Sharp HL, D'Angio GJ, Leonard AS. Portal hypertension following surgery, x-radiation, and actinomycin D therapy of nephroblastoma. Journal of Pediatrics 1971;78:1031-4.
281. Robert Cassady J. Clinical radiation nephropathy. International Journal of Radiation Oncology Biology Physics 1995;31:1249-56.
282. Romanini A, Galli G, D'Errico G, Carlesimo M, De Renzis C. Radioisotopic study of some organs after radiotherapy of the upper abdomen (author's translation) [Studio radioisotopico di alcuni organi dopo radioterapia dell'addome superiore]. Radiologia Medica 1981;67:757-61.
283. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatric Nephrology 1999;13:153-62.
284. Saddadi F, Hakemi M, Najafi I, Moghadam K, Ghavamzadeh A, Jahani M, et al.Chronic kidney disease after hematopoietic cell transplantation: frequency, risk factors, and outcomes. Transplantation Proceedings 2009;41:2895-7.
285. Saez RA, Slease RB, Strnad C, Selby GB, Confer DL, Epstein RB. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study. Bone Marrow Transplantation 1995;16:507-14.
286. Sagerman RH, Berdon WE, Baker DH. Renal atrophy without hypertension following abdominal irradiation in infants and children [Atrophie renale sans hypertension apres irradiation de l'abdomen chez le nourrisson et chez l'enfant]. Annales de Radiologie 1969;12:278-84.
287. Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al.Blood pressure and body mass index in long-term survivors of testicular cancer. Journal of Clinical Oncology 2005;23:4980-90.
288. Sakellari I, Bamichas G, Barbouti A, Mallouri D, Fragidis S, Apostolou C, et al.Older age, the number of preceded events of acute kidney injury and the in vivo t cell depletion are risk factors for kidney injury after hematopoietic cell transplantation. Haematologica 2010:447.
289. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatric Hematology and Oncology 2005;22:441-5.
290. Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, et al.Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. Journal of Clinical Oncology 1994;12:2423-31.
291. Schiff M Jr, Glazier WB. Nephrectomy: indications and complications in 347 patients. Journal of Urology 1977;118:930-1.
292. Schmidt D, Anderson L, Bingen K, Hoag J, Kupst MJ, Warwick AB. Late effects in adult survivors of childhood cancer: considerations for the general practitioner. Wisconsin Medical Journal 2010;109:98-108.
293. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, et al.Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. Journal of Clinical Oncology 2003;21:4083-91.
294. Schwartz MJ, Smith EB, Trost DW, Vaughan ED Jr. Renal artery embolization: clinical indications and experience from over 100 cases. British Journal of Urology International 2007;99:881-6.
295. Shamash J, O'Doherty CA, Oliver RT, Kelsey S, Gupta RK, Gallagher CJ, et al.Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?. Acta Oncologica 2000;39:857-63.
296. Shirasaki Y, Tsushima T, Saika T, Nasu Y, Kumon H. Kidney function after nephrectomy for renal cell carcinoma. Urology 2004;64:43-7.
297. Shirasaki Y, Tsushima T, Nasu Y, Kumon H. Long-term consequence of renal function following nephrectomy for renal cell cancer. International Journal of Urology 2004;11:704-8.
298. Shnorhavorian M, Friedman DL, Koyle MA. Genitourinary long-term outcomes for childhood cancer survivors. Current Urology Reports 2009;10:134-7.
299. Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, et al.Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Annals of Oncology 2004;15:276-82.
300. Silberzweig JE, Haller JO, Miller S. Ifosfamide: a new cause of rickets. American Journal of Roentgenology 1992;158:823-4.
301. Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schatzlein A, et al.Topotecan in combination with carboplatin: Phase I trial evaluation of two treatment schedules. Annals of Oncology 2002;13:399-402.
302. Skinner R, Pearson AD, Coulthard MG, Skillen AW, Hodson AW, Goldfinch ME, et al.Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemotherapy and Pharmacology 1991;28:81-92.
303. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. The influence of age on nephrotoxicity following chemotherapy in children. British Journal of Cancer 1992;18:S30-5.
304. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. Journal of Clinical Oncology 1993;11:173-90.
305. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. British Journal of Cancer 2000;82:1636-45.
306. Skinner R. Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology 2003;41:190-7.
307. Skinner R. Nephrotoxicity of cancer treatment in children. Pediatric Health 2010;4:519-38.
308. Skinner R. Nephrotoxicity-what do we know and what don't we know?. Journal of Pediatric Hematology/Oncology 2011;33(2):128-34.
309. Sloetjes KG, van den Bergh JP, Wesseling P, Otten BJ, Pieters GF, Hermus AR. Clinical presentation, treatment, and follow-up of 32 patients with a primary intracranial germinoma, registered during the previous 15 years in the Dutch Pathological-Anatomical National Automated Archive (PALGA) [Kliniek, behandeling en follow-up van 32 patienten met een primair intracranieel germinoom uit de afgelopen 15 jaar, geregistreerd in het Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (PALGA)]. Nederlands Tijdschrift voor Geneeskunde 2000;144:2264-8.
310. Smith GR, Thomas PR, Ritchey M, Norkool P. Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group. American Journal of Clinical Oncology 1998;21(1):58-63.
311. Sonn G, Shortliffe LM. Management of Wilms tumor: current standard of care. Nature Clinical Practice Urology 2008;5:551-60.
312. Spira EM, Jacobi C, Frankenschmidt A, Pohl M, von Schnakenburg C. Sonographic long-term study: paediatric growth charts for single kidneys. Archives of Disease in Childhood 2009;94:693-8.
313. Springate JE. Toxic nephropathies. Current Opinion in Pediatrics 1997;9:166-9.
314. Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. Journal of Cancer Survivorship 2007;1:261-74.
315. Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund G, et al.Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. Journal of Urology 1995;153:1812-6.
316. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Medical and Pediatric Oncology 2002;39:163-7.
317. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. Journal of Clinical Oncology 1991;9(12):2177-82.
318. Sukarochana K, Tolentino W, Kiesewetter WB. Wilms' tumor and hypertension. Journal of Pediatric Surgery 1972;7:573-6.
319. Talvensaari KK, Knip M, Lanning P, Lanning M. Clinical characteristics and factors affecting growth in long-term survivors of cancer. Medical and Pediatric Oncology 1996;26:166-72.
320. Talvensaari K, Knip M. Childhood cancer and later development of the metabolic syndrome. Annals ofMedicine 1997;29:353-5.
321. Tamaro P. Wilms' tumor: reached progress and future prospects [Il tumore di Wilms: progressi ottenuti e prospettive future]. Archivio Italiano di Urologia, Andrologia 1997;69:227-32.
322. Taylor RE. Morbidity from abdominal radiotherapy in the First United Kingdom Children's Cancer Study Group Wilms' Tumour Study. United Kingdom Children's Cancer Study Group. ClinicalOncology 1997;9:381-4.
323. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al.Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. Journal of Clinical Oncology 2003;21:1581-91.
324. Tefft M. Radiation related toxicities in National Wilms' Tumor Study Number 1. International Journal ofRadiation Oncology, Biology, Physics 1977;2:455-63.
325. Thomas PR, Griffith KD, Fineberg BB, Perez CA, Land VJ. Late effects of treatment for Wilms' tumor. International Journal ofRadiation Oncology, Biology, Physics 1983;9(5):651-7.
326. Tichelli A, Gratwohl A, Uhr M, Dazzi H, Hoffmann T, Stebler Gysi C, et al.[Health status and late complications following allogeneic bone marrow transplantation. A review] [Gesundheitszustand und Spatkomplikationen nach allogener Knochenmarktransplantation. Eine Ubersicht]. Schweizerische Medizinische Wochenschrift 1991;121:1473-81.
327. Tokuc G, Yalciner A, Kebudi R, Dogan S, Gorgun O, Ayan I. Renal dysfunctions secondary to ifosfamide treatment in children. Journal of Experimental & Clinical Cancer Research 1997;16:227-30.
328. Trimis G, Moschovi M, Papassotiriou I, Chrousos G, Tzortzatou-Stathopoulou F. Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease. Journal of Pediatric Hematology/Oncology 2007;29:309-14.
329. Turna B, Frota R, Kamoi K, Lin Y-C, Aron M, Desai MM, et al.Risk factor analysis of postoperative complications in laparoscopic partial nephrectomy. Journal of Urology 2008;179:1289-95.
330. van Waas M, Neggers SJ, Van Der Lelij A-J, Pieters R, Van Den Heuvel-Eibrink MM. The metabolic syndrome in adult survivors of childhood cancer, a review. Journal of Pediatric Hematology/Oncology 2010;32:171-9.
331. van Waas M, Neggers SJ, Pieters R, van den Heuvel-Eibrink MM. Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Annals of Oncology 2010;21:1121-6.
332. Veringa SJ, van Dulmen-den Broeder E, Kaspers GJ, Veening MA. Blood pressure and body composition in long-term survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer 2011;58(2):278-82.
333. Vio A, Reggiani A. Hypertension in Wilms' tumors [L'ipertensione nei tumori di Wilms]. Archivio Italiano di Urologia, Nefrologia, Andrologia 1970;43:155-62.
334. Von Der Weid NX, Erni BM, Mamie C, Wagner HP, Bianchetti MG. Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Nephrology Dialysis Transplantation 1999;14:1441-4.
335. Voute PA, de Kraker J. Ifosfamide in pediatric oncology. Seminars in Oncology 1992;19:2-6.
336. Voute PA, van den Berg H, Behrendt H, Michiels E, de Kraker J. Ifosfamide in the treatment of pediatric malignancies. Seminars in Oncology 1996;23:8-11.
337. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink Bakker A, Zwinderman AH, et al.Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. European Journal of Cancer 2004;40:1713-23.
338. Welch RJ, Pearson ADJ, Craft AW. Tetany in children treated with cisplatinum. Pediatric Hematology and Oncology 1987;4:167-70.
339. Wistow BW, McAfee JG, Sagerman RH, Thomas FD, Grossman ZD. Renal uptake of Tc-99m methylene diphosphonate after radiation therapy. Journal of Nuclear Medicine 1979;20:32-4.
340. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. Journal of Pediatrics 1985;106:659-63.
341. Wright KD, Green DM, Daw NC. Late effects of treatment for Wilms tumor. Pediatric Hematology and Oncology 2009;26:407-13.
342. Wu HY, Snyder HM III, D'Angio GJ. Wilms' tumor management. Current Opinion in Urology 2005;15:273-6.
343. Yanagisawa R, Nakazawa Y, Sakashita K, Tanaka M, Shikama N, Kamijo T, et al.Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies. Pediatric Transplantation 2009;13:737-45.
344. Yao MS, Mehta MP, Boyett JM, Li H, Donahue B, Rorke LB, et al.The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: a phase III study in a high-risk patient population. International Journal ofRadiation Oncology, Biology, Physics 1997;38:469-76.
345. Yaris N, Sozen E, Erduran E, Okten A, Orem A, Cakirbay H. Bone mineral metabolism and its relationship to leptin levels in survivors of childhood leukemia and lymphoma. Pediatric Hematology and Oncology 2005;22:489-98.
346. Yoshimura K, Yamauchi T, Maeda H, Kawai T. Cisplatin, vincristine, methotrexate, peplomycin, etoposide (COMPE) therapy for disseminated germ cell testicular tumors. International Journal of Urology 1997;4:47-51.
347. Zagars GK, Babaian RJ. Stage I testicular seminoma: rationale for postorchiectomy radiation therapy. International Journal ofRadiation Oncology, Biology, Physics 1987;13:155-62.
348. Zerin JM, Haliloglu M, Cohen MD. Growth of the solitary kidney after nephrectomy in children with unilateral Wilms' tumor. Pediatric Radiology 1996;26:547-52.
349. Zielinska E, Zubowska M, Bodalski J. Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children [Polimorfizm genu kodujacego transferaze S-glutationowa klasy P1 jako czynnik ryzyka nefrotoksycznego dzialania ifosfamidu u dzieci]. Polski MerkuriuszLekarski 2003;14:295-8.
350. Zorn KC, Gong EM, Orvieto MA, Gofrit ON, Mikhail AA, Msezane LP, et al.Comparison of laparoscopic radical and partial nephrectomy: effects on long-term serum creatinine. Urology 2007;69:1035-40.
351. Bailey S, Roberts A, Brock C, Price L, Craft AW, Kilkarni R, et al. Nephrotoxicity in survivors of Wilms' tumours in the North of England. British Journal of Cancer 2002;87:1092-8.
352. Cohen E, Fish BL, Moulder J. Mitigation of radiation nephropathy. Radiotherapy and Oncology 2010:S109.
353. Cozzi D, Ceccanti S, Mele E, Frediani S, Iaconelli R, Schiavetti A, et al.Renal function outcomes after nephrectomy or nephron-sparing surgery for unilateral renal tumor in childhood. Pediatric Blood and Cancer 2010:793.
354. D'Angio GJ, Tefft M, Breslow N, Meyer JA. Radiation therapy of Wilms' tumor: results according to dose, field, post-operative timing and histology. International Journal of Radiation Oncology, Biology, Physics 1978;4:769-80.
355. Eckstein OS, O'Hear CE, Chi S, Lehmann LE, Duncan CN. High-dose chemotherapy with autologous stem-cell rescue in pediatric patients with CNS tumors: toxicity and outcomes. Biology of Blood and Marrow Transplantation. 2010:S247.
356. Janda J, Koutecky J, Lukes M, Lukesova M, Malis J. The solitary kidney in patients after nephrectomy in Wilm's tumor. Ceskoslovenska Pediatrie 1993;48:577-80.
357. Kieran K, Giel DW, Davidoff AM, Williams MA. Urolithiasis in patients treated for childhood cancer: does altered calcium metabolism play a role?. Journal of Urology. 2010:e409.
358. Li MJ, Huang Y, Tang DX, Zhou YB, Tang HF, Liang JF. [Treatment of advanced Wilms' tumor]. Zhonghua Zhong Liu Za Zhi 2006;28:791-5.
359. Madden JR, Hemenway M, Dorneman L, Strecker R, Foreman N. Outpatient cisplatin for average risk medulloblastoma: 15 year experience. Neuro-Oncology. 2010:ii111.
360. Matsuyama T, Kato K, Hanada R, Kawa K, Okamura J, Tsuchida M, et al.[Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia]. Rinsho Ketsueki 2002;43:527-37.
361. Pugachev AG. Conservative surgery-a basic principle of childhood urology [Organosokhraniaiushchie Operatsii Osnovnoe Napravlenie v Detskoi Urologii]. Urologiia 2004;4:3-5.
362. Radvansky J, Slaby K, Radvanska J, Malis J, Eckschalger T, Sulc J, et al.Late effect of treatment of nephroblastoma in patients treated in 1980-2001 in a single centre [Pozdni nasledky Wilmsova tumoru a jeho lecby u pacientu lecenych v letech 1980-2001 na jedinem pracovisti.]. Klinikal Onkologie 2010;23:245-55.
363. Sakellari I, Bamichas G, Barbouti A, Mallouri D, Fragidis S, Yannaki E, et al.Kidney injury as an early complication after haematopoietic cell transplantation: incidence, risk factors and outcome. Bone Marrow Transplantation 2010:S107.
364. Schwartz L. Survival in adolescents and young adults with cancer in childhood. Medicina 2001;61:401-5.
365. Sierota D, Stefanowicz J, Aleszewicz-Baranowska J, Birkholz D, Kosiak W, Adamkiewicz-Drozynska E, et al.Late side-effects of treatment in patients with nephroblastoma [Odlegle nastepstwa leczenia przeciwnowotworowego u dzieci z rozpoznaniem nerczaka zarodkowego]. Medycyna Wieku Rozwojowego 2005;9:517-22.
366. Stronska E, Zwolinska D, Sawicz-Birkowska K, Makulska I, Magier K, Czernik J. Assessment of function of the only kidney in children after nephrectomy due to Wilms tumor [Ocena czynnosci jedynej nerki u dzieci po nefrektomii z powodu guza Wilmsa.]. Polski MerkuriuszLekarski 2003;14:311-4.
367. Terenziani M, Indolfi P, Ardissino G, Bianchi M, Biasoni D, Catania S, et al.Bilateralwilms tumour (stage V): a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Wilms Tumour 2003 Cooperative Protocol. Pediatric Blood and Cancer 2010:883.
368. Beevers G, Lip GY, O'Brien E. ABC of Hypertension. 5th Edition. London, United Kingdom: BMJ Books, 2007.
369. Breitz H. Clinical aspects of radiation nephropathy. Cancer Biotherapy & Radiopharmaceuticals 2004;19(3):359-62.
370. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clinical Infectious Diseases 2009;49:225-32.
371. De Graaf SS, Van Gent H, Reitsma-Bierens WC, Van Luyk WH, Dolsma WV, Postma A. Renal function after unilateral nephrectomy for Wilms' tumour: the influence of radiation therapy. European Journal of Cancer 1996;32A(3):465-9.
372. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. The Lancet 1997;350(9074):326-9.
373. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. European Journal of Cancer 2009;45(6):992-1005.
374. Grimes DA, Schultz KF. Cohort studies: marching towards outcomes. The Lancet 2002;359:341-5.
375. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
376. Hoang K, Tan JC, Derby G, Blouch KL, Masek M, Ma I, et al.Determinants of glomerular hypofiltration in aging humans. Kidney International 2003;64(4):1417-24.
377. Kremer LC, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of anthracycline-induced clinicalheartfailure in children: a systematic review. Annals of Oncology 2002;13(4):503-12.
378. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treatment Reviews 1999;25(1):47-58.
379. Laupacis A, Wells G, Richardson WS, Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. Journal of the American Medical Association 1994;272:234-7.
380. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. Q J Med 2010;103(7):449-59.
381. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al.Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet 2010;375:2073-81.
382. Mulder RL, Van Dalen EC, Bresters D, Loke Y, Leclerq E, Postma A, et al.Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD008205.pub2]
383. Nathan PC, Ford JS, Henderson TO, Hudson MM, Emmons KM, Casillas JN, et al.Health behaviors, medical care, and interventions to promote healthy living in theChildhoodCancerSurvivor Study cohort. Journal of Clinical Oncology 2009;27(14):2363-73.
384. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Disease 2002;39:S1-S266.
385. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al.Chronic health conditions in adult survivors of childhood cancer. New England Journal of Medicine 2006;355:1572-82.
386. Pietilä S, Ala-Houhala M, Lenko HL, Harmoinen AP, Turjanmaa V, Mäkipernaa A. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment. Pediatric Blood and Cancer 2005;44:363-9.
387. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. European Journal of Cancer 2006;42(18):3191-8.
388. van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, et al. High risk of symptomatic cardiac events in childhood cancer survivors. Journal of Clinical Oncology 2012;30(13):1429-37.
389. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Annals of Internal Medicine 2007;147(8):573-77.
390. Wasilewski-Masker K, Mertens AC, Patterson B, Meacham LR. Severity of health conditions identified in a pediatric cancer survivor program. Pediatric Blood and Cancer 2010;54(7):976-82.
391. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization, 2002.